Search Results
How the AURA3 trial has changed conversations about re-biopsy in second-line lung cancer treatment
Repeat biopsy in lung cancer patients with EGFR mutation
The FLAURA Trial in EGFR+ NSCLC
EBUS and CT-guided biopsy in repeat biopsies of patients with progressive lung cancer
aura3
The changing landscape of NSCLC diagnosis, monitoring and treatment
Watch Drs. Leighl, Piotrowska, & Shu discuss #LungCancer - https://bit.ly/3QZG91q
AURA3
Heterogeneity of NSCLC and precipitating oncogenic driver mutations
EGFR Initial Treatment, Acquired Resistance and Q&A with H. Jack West, MD and Helena Yu, MD
Osimertinib’s Value in EGFR-Mutant NSCLC
Deciphering the data in EGFR - Mutant NSCLC
